What was Abbott Laboratories' primary focus in 1993?

In 1993, Abbott Laboratories operated as a diversified healthcare company with significant interests in pharmaceuticals, diagnostics, and likely medical devices and nutritional products. The 10-K filing would detail the performance and strategic initiatives across these core business segments.

Where can I find the specific financial results for 1993?

The specific financial results, including revenue, net income, and balance sheet details for the fiscal year ending December 30, 1993, would be located within the detailed financial statements and the Management's Discussion and Analysis (MD&A) section of the full 10-K report, which is not fully provided in this excerpt.

What were the major risks or challenges facing Abbott in 1993?

While not detailed in this excerpt, the full 10-K report would typically include a 'Risk Factors' section or discuss challenges within the MD&A. These could have included competitive pressures, regulatory changes in the healthcare industry, pricing pressures, and the success of new product development and launches.

How can this 1994 filing help me understand Abbott's current business?

This filing provides historical context for Abbott Laboratories. By understanding its performance, strategic direction, and market position in 1993, investors can better evaluate its long-term growth trajectory, the evolution of its business segments, and its resilience over time. It serves as a baseline for appreciating the company's development since that period.

ABT 10-K FY1993 Annual Report — Revenue, Net Income, EPS

Summary

Abbott Laboratories' 1993 Annual Report (10-K), filed in March 1994, details the company's financial performance and operational highlights for the fiscal year ending December 30, 1993. As a diversified healthcare company, Abbott's results reflect its diverse business segments, likely including pharmaceuticals, diagnostics, and medical devices. Investors would be keen to understand the company's revenue growth, profitability trends, and any significant developments or challenges faced during the year. This filing provides a snapshot of Abbott's position in the healthcare market at a crucial time. While specific financial figures and segment breakdowns are not detailed in the provided excerpt, the report serves as a foundational document for assessing the company's historical performance, strategic direction, and its ability to navigate the evolving healthcare landscape. Investors should look for information on market share, product pipelines, and any regulatory or competitive factors that may have influenced performance.

Key Highlights

1The filing represents Abbott Laboratories' official annual financial and operational disclosure for the fiscal year ending December 30, 1993.
2This 10-K report provides a comprehensive overview of Abbott's business, financial condition, and results of operations.
3Investors can use this report to assess the company's historical performance and strategic positioning within the healthcare industry.
4The filing would typically include detailed financial statements (income statement, balance sheet, cash flow statement) and management's discussion and analysis (MD&A).
5Key areas of focus for investors would be revenue trends, profitability, debt levels, and significant capital expenditures or acquisitions.
6The report offers insights into the company's operational segments, which likely include pharmaceuticals, diagnostics, and potentially medical devices or nutritional products.

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 1993

Summary

Key Highlights

Frequently Asked Questions